Mobile

A Phase II, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® added to Thalidomide-Dexamethasone Standard Treatment in Subjects with Multiple My...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-004624-38

A Phase II, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® added to Thalidomide-Dexamethasone Standard Treatment in Subjects with Multiple Myeloma who are Refractory to or Have Relapsed after Primary Therapy for Multiple Myeloma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

to assess the safety and efficacy of adding Velcade® to thalidomide and dexamethasone (Thal-Dex) standard treatment in subjects with multiple myeloma who are refractory to or have relapsed after their primary therapy for multiple myeloma. The efficacy response will be measured by the response rate of the disease.

Critère d'inclusion

  • Multiple myeloma

Liens